MOJ
eISSN: 2381-179X
Submit manuscript...
Case Report Volume 15 Issue 1
Adjuvant cannabidiol in the management of canine cutaneous squamous cell carcinoma: a long-term survival case and translational review
Patricia Beck Eichler-Barker, Evelyn da Rocha Mendes Pereira
Received: November 24, 2025 | Published: December 10, 2025
Citation: Eichler-Barker PB, Pereira ERM. Adjuvant cannabidiol in the management of canine cutaneous squamous cell carcinoma: a long-term survival case and translational review. MOJ Clin Med Case Rep. 2025;15(1):34-35 DOI: 10.15406/mojcr.2025.15.00483
Abstract
Cutaneous squamous cell carcinoma (SCC) is a common epithelial malignancy in dogs and shares many molecular and pathological features with human cutaneous SCC. Standard management relies on surgical excision and radiotherapy; however, recurrence remains frequent when margins are narrow or anatomic constraints limit complete tumor removal. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, exhibits anti-inflammatory, anti-proliferative, pro-apoptotic, and anti-angiogenic activity in several cancer models. This manuscript presents a clinical case of canine SCC treated with adjuvant oral CBD following marginal surgical excision and integrates a translational literature review. The patient received full-spectrum 1% CBD (>0.3% THC) during the day and 3% CBD (<0.3% THC) at night for 60 days. No early recurrence was observed, biochemical parameters remained within normal limits, and the dog remains alive 14 months after diagnosis. Mechanistic evidence from preclinical and comparative oncology studies suggests that CBD modulates apoptosis, autophagy, angiogenesis, and immune pathways relevant to SCC progression. These findings support further investigation of CBD as an adjunct therapy in veterinary oncology.
Keywords: cannabidiol, inhibition, oncology, radiation
©2025 Eichler-Barker, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.